Dataset Information

Quantitative proteomics analysis of paired colorectal cancer and non-tumorigenic tissues reveal proteins and pathways perturbed in colorectal cancer

ABSTRACT: Proteomics is a dynamic field emerged dramatically the post genomic era which has been extensively employed to study altered protein expression to gain insight into the development process and pathways involved in cancer and uncover potential protein markers. Membrane proteomes of an expanded cohort of paired CRC and adjacent non-tumorigenic tissues (1 female and 7 males) were profiled using high resolution nanoLC-MS/MS-based proteomics, which identified 1,000-1,300 proteins in each of the two tissue types. 184 proteins were differentially expressed (P < 0.05, fold change > 1.5); 69 proteins were up- regulated and 115 proteins were down-regulated in the CRC tissues relative to non-tumorigenic tissues.

INSTRUMENT(S): LTQ Orbitrap Elite

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Colon

DISEASE(S): Colon Cancer

SUBMITTER: Manveen Sethi

LAB HEAD: Dr. Susan Fanayan

PROVIDER: PXD001676 | Pride | 2016-06-15

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 48

Publications

Quantitative proteomic analysis of paired colorectal cancer and non-tumorigenic tissues reveals signature proteins and perturbed pathways involved in CRC progression and metastasis.

Sethi Manveen K MK Thaysen-Andersen Morten M Kim Hoguen H Park Cheol Keun CK Baker Mark S MS Packer Nicolle H NH Paik Young-Ki YK Hancock William S WS Fanayan Susan S

Journal of proteomics 20150606

Modern proteomics has proven instrumental in our understanding of the molecular deregulations associated with the development and progression of cancer. Herein, we profile membrane-enriched proteome of tumor and adjacent normal tissues from eight CRC patients using label-free nanoLC-MS/MS-based quantitative proteomics and advanced pathway analysis. Of the 948 identified proteins, 184 proteins were differentially expressed (P<0.05, fold change>1.5) between the tumor and non-tumor tissue (69 up-re ...[more]

PMID: 26054784

Similar Datasets

Project description:Breast cancers contain a minority population of cancer cells characterized by CD44 expression but low or undetectable levels of CD24 (CD44+CD24-/low) that have higher tumorigenic capacity than other subtypes of cancer cells. METHODS: We compared the gene-expression profile of CD44+CD24-/low tumorigenic breast-cancer cells with that of normal breast epithelium. Differentially expressed genes were used to generate a 186-gene invasiveness gene signature (IGS), which was evaluated for its association with overall survival and metastasis-free survival in patients with breast cancer or other types of cancer. RESULTS: There was a significant association between the IGS and both overall and metastasis-free survival (P<0.001, for both) in patients with breast cancer, which was independent of established clinical and pathological variables. When combined with the prognostic criteria of the National Institutes of Health, the IGS was used to stratify patients with high-risk early breast cancer into prognostic categories (good or poor); among patients with a good prognosis, the 10-year rate of metastasis-free survival was 81%, and among those with a poor prognosis, it was 57%. The IGS was also associated with the prognosis in medulloblastoma (P=0.004), lung cancer (P=0.03), and prostate cancer (P=0.01). The prognostic power of the IGS was increased when combined with the wound-response (WR) signature. CONCLUSIONS: The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors. This genetic signature of tumorigenic breast-cancer cells was even more strongly associated with clinical outcomes when combined with the WR signature in breast cancer. Expression profling was performed on 6 tumorigenic, 3 non tumorigenic samples of breast tumors and 3 normal breast samples on two different platforms GPL96 and GPL97. A gene signature was derived by comparing the gene expressions of 6 tumorigenic samples with 3 normal breast samples.

			Action	DRS
	Non-tumor-1_mzXML.zip	Other
	Non-tumor-1_raw.zip	Other
	Non-tumor-1_xml.xml	Xml
	Non-tumor-2_mzXML.zip	Other
	Non-tumor-2_raw.zip	Other